We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

BioFocus Signs Agreement with Aviva Investors


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioFocus Signs Agreement with Aviva Investors"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

BioFocus and Aviva Investors have announced the signing of a pre-let agreement for the new Robinson Building, a 60,000 square foot (5,587square metres) facility at Chesterford.

BioFocus will unite the majority of its drug discovery groups within the new complex, affording the company a unique position amongst CROs for support of integrated projects.

Chris Newton of BioFocus explains the decision to move: “BioFocus has been expanding its research activities at Chesterford Park, bringing our expertise in different areas such as structural biology, complex cell assays, and medicinal chemistry closer together. Moving many of these teams into a single, modern and efficient building is an important step forward for the company and will bring added synergies to both our business model and to our scientists.”

Julian Cobourne, Asset Manager for Aviva Investors says: “Chesterford Research Park has provided significant support to BioFocus in meeting its property needs over the years and it has been great to work with them to design a much more efficient laboratory building to meet their future requirements.”

Martin Sylvester of Churchmanor Estates (the joint development partner of Aviva Investors at Chesterford Research Park) commented: “This is great news for Chesterford Research Park and also for the South Cambridge life sciences cluster. Aside from the AstraZeneca deal, this is the largest pre-let in the Cambridge area since 2011 and represents a very significant investment in the region’s economy.”

As the Robinson Building already has outline planning permission, construction is expected to start on site almost immediately.

The building has been designed as two wings, linked by an impressive two-storey atrium and a landscaped courtyard. It has an attractive curved profile which will be enhanced by extensive green landscaping.

Advertisement